A Phase 1 interventional study of taladegib and nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Endeavor Biomedicines, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 26 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Endeavor Biomedicines, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia — 11 open to participants now, 16 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Australia.
Among the 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia, this one is the 52nd largest by planned enrollment, is one of 8 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 1 of the 15 other live ones, and was the 62nd registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →11 of the 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, United States, Argentina and 20 more countries
Ages 40+
Avalyn Pharma Inc. · Sites in Australia, Canada, Germany and 4 more countries
Ages 40+
Rein Therapeutics · Sites in Australia, United States, Bulgaria and 4 more countries
Ages 40+
AbbVie · Sites in Australia, United States, Bulgaria and 14 more countries
Ages 40+
Contineum Therapeutics · Sites in Australia, Argentina, Belgium and 16 more countries
Ages 40+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 26 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 1900; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 57 is close to the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 165 across the 64 interventional studies. Of the 45 that completed or were terminated, 33 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 64 have an industry lead sponsor. The 10 most frequent:
Endeavor Biomedicines, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Endeavor Biomedicines, Inc. has 4 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07194382Avalyn Pharma Inc.AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | 2026-12 |
| NCT07036523Boehringer IngelheimA Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment | 2027-03-11 |
| NCT06588686Vicore Pharma ABA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | 2027-05 |
| NCT07682337SCBIO Inc.Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects | 2027-06-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Idiopathic Pulmonary Fibrosis with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to:
This study will enroll 4 cohorts (groups) of participants. Each cohort will experience a different duration of treatment and sequestering (being housed) at the clinical site, followed by a 14-day follow-up period for safety evaluation. The longest duration of treatment for any cohort is 30 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History or presence (per participant history) of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort will receive multiple days of nintedanib twice a day to see its effect on a single dose of taladegib.
Drug: taladegib · Drug: nintedanib
This cohort will receive multiple days of pirfenidone three times a day to see its effect on a single dose of taladegib.
Drug: taladegib · Drug: pirfenidone
This cohort will receive multiple days of taladegib once a day to see its effect on a single dose of pirfenidone.
Drug: taladegib · Drug: pirfenidone
This cohort will receive a single dose of taladegib to measure its pharmacokinetic profile.
Drug: taladegib
low, medium or high dose tablet administered once, or once a day
Also known as: ENV-101
150 mg capsule administered twice a day
One, two or three 267 mg tablets administered three times a day
Three 267 mg tablets administered once
Cohort 1: Taladegib (ENV-101) maximum blood concentration (Cmax) after administration alone and after coadministration with nintedanib
Time frame: Day 1 and Day 13
Cohort 1: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with nintedanib
Time frame: Day 1 and Day 13
Cohort 1: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with nintedanib
AUC\[0-t\] represents "area under the concentration-time curve" and measures the amount of drug that is present in the blood from the time of administration to a given time t
Time frame: Day 1 and Day 13
Cohort 1: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with nintedanib
Time frame: Day 1 and Day 13
Cohort 1: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with nintedanib
Time frame: Day 1 and Day 13
Cohort 1: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with nintedanib
Time frame: Day 1 and Day 13
Cohort 1: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with nintedanib
K\[el\] represents the fraction of a drug that is removed from the body per unit of time.
Time frame: Day 1 and Day 13
Cohort 1: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with nintedanib
Apparent oral clearance represents the volume of plasma cleared of drug per unit time after oral administration.
Time frame: Day 1 and Day 13
Cohort 1: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with nintedanib
Apparent volume of distribution signifies how extensively a drug distributes throughout the body, accounting for bioavailability.
Time frame: Day 1 and Day 13
Cohort 2: Taladegib maximum blood concentration (Cmax) after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 2: Time of taladegib maximum blood concentration (Tmax) after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 2: Taladegib absorption to time t (AUC[0-t]) after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 2: Taladegib total absorption (AUC[0-infinity]) after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 2: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 2: Taladegib half-life in the blood (T1/2) after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 2: Elimination rate constant (K[el]) for taladegib after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 2: Apparent oral clearance (CL/F) of taladegib after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 2: Apparent volume of distribution (Vz/F) of taladegib after administration alone and after coadministration with pirfenidone
Time frame: Day 1 and Day 27
Cohort 3: Pirfenidone maximum blood concentration (Cmax) after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 3: Time of pirfenidone maximum blood concentration (Tmax) after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 3: Pirfenidone absorption to time t (AUC[0-t]) after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 3: Pirfenidone total absorption (AUC[0-infinity]) after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 3: Pirfenidone extrapolated total absorption (AUC[extrapolated]) after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 3: Pirfenidone half-life in the blood (T1/2) after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 3: Elimination rate constant (K[el]) for pirfenidone after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 3: Apparent oral clearance (CL/F) of pirfenidone after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 3: Apparent volume of distribution (Vz/F) of pirfenidone after administration alone and after coadministration with taladegib
Time frame: Day 1 and Day 6
Cohort 4: Taladegib maximum blood concentration (Cmax) after administration alone
Time frame: Day 1
Cohort 4: Time of taladegib maximum blood concentration (Tmax) after administration alone
Time frame: Day 1
Cohort 4: Taladegib absorption to time t (AUC[0-t]) after administration alone
Time frame: Day 1
Cohort 4: Taladegib total absorption (AUC[0-infinity]) after administration alone
Time frame: Day 1
Cohort 4: Taladegib extrapolated total absorption (AUC[extrapolated]) after administration alone
Time frame: Day 1
Cohort 4: Taladegib half-life in the blood (T1/2) after administration alone
Time frame: Day 1
Cohort 4: Elimination rate constant (K[el]) for taladegib after administration alone
Time frame: Day 1
Cohort 4: Apparent oral clearance (CL/F) of taladegib after administration alone
Time frame: Day 1
Cohort 4: Apparent volume of distribution (Vz/F) of taladegib after administration alone
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 6 months is below that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY2940680
Idiopathic Pulmonary Fibrosis →
Endeavor Biomedicines, Inc.